tiprankstipranks
Trending News
More News >
CG Oncology, Inc. (CGON)
NASDAQ:CGON
US Market
Advertisement

CG Oncology, Inc. (CGON) AI Stock Analysis

Compare
169 Followers

Top Page

CGON

CG Oncology, Inc.

(NASDAQ:CGON)

Rating:49Neutral
Price Target:
$26.00
▼(-0.38%Downside)
CG Oncology, Inc. faces financial hurdles typical of early-stage biotech companies, with no current revenue and reliance on external funding. While technical indicators show neutral momentum, the valuation reflects challenges in achieving profitability. Promising trial results provide a potential future catalyst, but immediate financial and operational improvements are necessary to enhance the company's stock outlook.
Positive Factors
Launch and Uptake Potential
There is confidence in creto's launch and uptake potential, which should outperform the early trajectory observed with other therapies.
Market Opportunity
The analyst remains positive on the market opportunity and label expansion potential for creto.
Product Differentiation
Creto is meaningfully differentiated by its durability and safety data, which supports further upside for creto in additional indications and combinations with other therapies.
Negative Factors
Adverse Events Concerns
Durability for creto may be slightly more impressive but is awaiting further follow-up.
Competitor Comparison
Dr. Ghodoussipour was a bit hesitant on the higher frequency of grade 3+ TRAEs and discontinuations with TAR-200.
Data Risk
Creto's clinical positioning in BCG-unresponsive, high-risk NMIBC was strengthened by the disappointing TAR-200 data.

CG Oncology, Inc. (CGON) vs. SPDR S&P 500 ETF (SPY)

CG Oncology, Inc. Business Overview & Revenue Model

Company DescriptionCG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.
How the Company Makes MoneyCG Oncology, Inc. makes money primarily through the development and commercialization of its proprietary oncolytic immunotherapy treatments. The company's revenue model includes the potential for milestone payments, royalties, and licensing fees from partnerships with larger pharmaceutical companies. These partnerships may involve collaborative research and development agreements or licensing agreements for the distribution and marketing of CG Oncology's therapies. Additionally, the company may pursue direct commercialization of its products, subject to successful clinical trials and regulatory approval, to generate revenue through product sales.

CG Oncology, Inc. Financial Statement Overview

Summary
CG Oncology, Inc. is experiencing financial challenges typical of early-stage biotech firms, with no revenue and significant operating losses. However, the strong equity position and cash reserves provide some stability, despite the reliance on external funding for operations.
Income Statement
20
Very Negative
CG Oncology, Inc. reported zero revenue in the latest year, indicating challenges in generating income. The company has experienced consistent losses with deteriorating EBIT and EBITDA margins, reflecting operational inefficiencies and potential barriers in monetizing its biotechnology developments.
Balance Sheet
65
Positive
The company's strong equity base relative to total assets, demonstrated by a high equity ratio, provides a solid financial foundation. However, the minimal debt levels and high cash reserves suggest limited leverage but also an underutilization of potential financing for growth.
Cash Flow
30
Negative
The negative free cash flow and significant negative operating cash flow highlight ongoing cash burn issues. Despite substantial financing inflows, the company is heavily reliant on external funding for operations, which could pose risks if such funding diminishes.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue1.14M204.00K191.00K10.36M
Gross Profit1.14M204.00K176.00K10.35M
EBITDA-114.63M-55.43M-35.23M-12.38M
Net Income-88.04M-48.61M-35.44M-12.84M
Balance Sheet
Total Assets754.80M199.30M147.75M58.69M
Cash, Cash Equivalents and Short-Term Investments742.00M187.67M143.48M53.61M
Total Debt238.00K461.00K16.30M15.48M
Total Liabilities21.42M14.51M22.57M18.44M
Stockholders Equity733.38M184.79M125.18M40.25M
Cash Flow
Free Cash Flow-78.95M-45.68M-29.82M-13.75M
Operating Cash Flow-78.71M-45.68M-29.80M-13.65M
Investing Cash Flow-300.76M-121.19M-55.35M-97.00K
Financing Cash Flow628.28M87.00M119.69M15.45M

CG Oncology, Inc. Technical Analysis

Technical Analysis Sentiment
Negative
Last Price26.10
Price Trends
50DMA
26.17
Negative
100DMA
25.07
Positive
200DMA
28.51
Negative
Market Momentum
MACD
0.08
Positive
RSI
48.77
Neutral
STOCH
37.48
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CGON, the sentiment is Negative. The current price of 26.1 is below the 20-day moving average (MA) of 26.43, below the 50-day MA of 26.17, and below the 200-day MA of 28.51, indicating a bearish trend. The MACD of 0.08 indicates Positive momentum. The RSI at 48.77 is Neutral, neither overbought nor oversold. The STOCH value of 37.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CGON.

CG Oncology, Inc. Risk Analysis

CG Oncology, Inc. disclosed 81 risk factors in its most recent earnings report. CG Oncology, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

CG Oncology, Inc. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (56)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
56
Neutral
$2.15B-31.34%-54.85%-79.25%
56
Neutral
$6.23B21.98-28.61%4.90%10.73%-32.66%
56
Neutral
$2.18B-38.04%-82.38%-164.76%
54
Neutral
$1.77B-70.58%100.03%64.22%
49
Neutral
$1.99B-16.57%
43
Neutral
$2.10B-23.34%-14.19%
37
Underperform
$1.98B-84.04%-2.53%
* General Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CGON
CG Oncology, Inc.
26.10
-5.23
-16.69%
COGT
Cogent Biosciences
12.07
2.68
28.54%
IDYA
IDEAYA Biosciences
24.50
-17.75
-42.01%
ARQT
Arcutis Biotherapeutics
14.86
5.29
55.28%
BEAM
Beam Therapeutics
21.72
-10.32
-32.21%
IRON
Disc Medicine
60.61
16.79
38.32%

CG Oncology, Inc. Corporate Events

Executive/Board Changes
CG Oncology Appoints Interim CFO After Resignation
Neutral
Jul 11, 2025

CG Oncology, Inc. announced that its Chief Financial Officer, Corleen Roche, has resigned, with her departure effective on August 5, 2025. The company has appointed Robert Lapetina as the interim principal financial and accounting officer, effective the same date, until a permanent replacement is found.

The most recent analyst rating on (CGON) stock is a Buy with a $66.00 price target. To see the full list of analyst forecasts on CG Oncology, Inc. stock, see the CGON Stock Forecast page.

Executive/Board ChangesShareholder Meetings
CG Oncology Holds 2025 Annual Stockholders Meeting
Neutral
Jun 6, 2025

On June 5, 2025, CG Oncology, Inc. held its 2025 Annual Meeting of Stockholders where key decisions were made regarding the company’s leadership and auditing practices. The stockholders elected three Class I directors to serve until the 2028 Annual Meeting and ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (CGON) stock is a Buy with a $86.00 price target. To see the full list of analyst forecasts on CG Oncology, Inc. stock, see the CGON Stock Forecast page.

Product-Related AnnouncementsBusiness Operations and Strategy
CG Oncology Announces Promising Phase 3 Trial Results
Positive
Apr 28, 2025

On April 26, 2025, CG Oncology announced promising results from its Phase 3 BOND-003 clinical trial at the American Urological Association Annual Meeting. The trial data showed a 75.5% complete response rate at any time for patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer treated with cretostimogene grenadenorepvec. The 24-month complete response rate was 42.3%, with a median duration of response of 28 months. Additionally, 97.3% of patients remained free from progression to muscle-invasive disease, and the treatment was well-tolerated with no severe adverse events reported. Cohort P also showed a high-grade recurrence-free survival rate of 90.5% at 3 and 9 months. These results position cretostimogene as a potential breakthrough therapy for bladder cancer, offering distinct advantages over existing treatments.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 23, 2025